"Emerging Psychiatric Drugs: The Impact of Neuroscience Renaissance"

In the early 2000s, major pharmaceutical companies faced a decline in psychiatric drug innovation as their blockbuster treatments for depression and schizophrenia neared generic status. This led to a shift away from mental health research in favor of other therapeutic areas. However, there is now optimism for a resurgence in neuroscience-driven drug development, offering hope for new and improved psychiatric medicines.